Alembic gets USFDA nod for generic medication
Alembic Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) to market Dabigatran Etexilate Capsules (110 mg), a generic product for the prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. This product is therapeutically equivalent to Boehringer Ingelheim's Pradaxa Capsules. With this approval, Alembic now has a total of 211 ANDA approvals from the USFDA. Shares of Alembic Pharmaceuticals closed 3.17% lower at Rs 1,076 apiece on the BSE
)
Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic product indicated for prophylaxis of deep vein thrombosis. The company has received approval from the US Food and Drug Administration (USFDA) to market Dabigatran Etexilate Capsules (110 mg), the drug firm said in a regulatory filing.
Dabigatran Etexilate Capsules are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. The approved product is therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals Inc.'s Pradaxa Capsules (110 mg).
The company said it now has a cumulative total of 211 ANDA (abbreviated new drug application) approvals from the USFDA. Shares of the company on Tuesday closed 3.17 percent down at Rs 1,076 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
05:34 PM IST
Alembic, Aurobindo recall drugs in US market 
Alembic Pharmaceuticals Records Impressive Q1 Profit of Rs 120.6 Crore, India Revenues Grow by 9 per cent
Stocks in focus: VRL Logistics, Sun Pharma, Paytm, other stocks worth tracking
Alembic Pharma gets USFDA nod to market generic antidepressant drug